dc.contributor.author | Grünwald, V | |
dc.contributor.author | Chirovsky, D | |
dc.contributor.author | Cheung, WY | |
dc.contributor.author | Bertolini, F | |
dc.contributor.author | Ahn, M-J | |
dc.contributor.author | Yang, M-H | |
dc.contributor.author | Castro, G | |
dc.contributor.author | Berrocal, A | |
dc.contributor.author | Sjoquist, K | |
dc.contributor.author | Kuyas, H | |
dc.contributor.author | Auclair, V | |
dc.contributor.author | Guillaume, X | |
dc.contributor.author | Joo, S | |
dc.contributor.author | Shah, R | |
dc.contributor.author | Harrington, K | |
dc.contributor.author | GLANCE H&N STUDY Investigators, | |
dc.date.accessioned | 2020-04-02T15:02:14Z | |
dc.date.issued | 2020-03-01 | |
dc.identifier.citation | Oral oncology, 2020, 102 pp. 104526 - ? | |
dc.identifier.issn | 1368-8375 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3577 | |
dc.identifier.eissn | 1879-0593 | |
dc.identifier.doi | 10.1016/j.oraloncology.2019.104526 | |
dc.description.abstract | OBJECTIVES: Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting. MATERIALS AND METHODS: A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characteristics, treatment and survival data. RESULTS: Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54-67), 84% male, and 70% Eastern Cooperative Oncology Group performance status 0-1; 32% had oral cavity and 30% oropharyngeal cancers. The most common first-line regimen across all countries consisted of platinum-based combinations (73%), including platinum + 5-fluorouracil (5-FU) (26%), cetuximab + platinum ± 5-FU (22%), or taxane + platinum ± 5-FU (16%). However, use of different platinum-based combinations varied substantially; administration of cetuximab + platinum ± 5-FU was frequent in Italy (81%), Germany (46%) and Spain (38%), whereas use in other countries was limited. Median follow-up was 22.6 months (95% confidence interval [CI]: 21.5-24.6 months). Median real-world overall survival was only 8.0 months (95% CI: 7.0-8.0), with one-year survival reaching only 30.9% (95% CI: 27.5-34.3). CONCLUSION: Systemic therapies used in clinical practice for patients with R/M HNSCC vary substantially across countries. Prognosis remains poor in this patient population, highlighting the need for newer, more efficacious treatments. | |
dc.format | Print-Electronic | |
dc.format.extent | 104526 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | GLANCE H&N STUDY Investigators | |
dc.title | Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-12-13 | |
rioxxterms.versionofrecord | 10.1016/j.oraloncology.2019.104526 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-03 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Oral oncology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.publication-status | Published | |
pubs.volume | 102 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Harrington, Kevin | |